MedPath

Children's Oncology Group

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

Phase 3
Active, not recruiting
Conditions
Hematopoietic and Lymphatic System Neoplasm
Leukemia
Lymphoma
Interventions
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Other: Placebo Administration
First Posted Date
2017-02-17
Last Posted Date
2024-10-01
Lead Sponsor
Children's Oncology Group
Target Recruit Count
173
Registration Number
NCT03057054
Locations
πŸ‡ΊπŸ‡Έ

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States

πŸ‡ΊπŸ‡Έ

University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States

πŸ‡ΊπŸ‡Έ

Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 40 locations

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phase 3
Active, not recruiting
Conditions
B Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
T Acute Lymphoblastic Leukemia
Interventions
First Posted Date
2017-01-02
Last Posted Date
2025-06-11
Lead Sponsor
Children's Oncology Group
Target Recruit Count
475
Registration Number
NCT03007147
Locations
πŸ‡ΊπŸ‡Έ

Children's Hospital of Alabama, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

USA Health Strada Patient Care Center, Mobile, Alabama, United States

πŸ‡ΊπŸ‡Έ

Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 223 locations

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Phase 2
Recruiting
Conditions
Recurrent B Acute Lymphoblastic Leukemia
Recurrent B Lymphoblastic Lymphoma
Refractory B Acute Lymphoblastic Leukemia
Refractory B Lymphoblastic Lymphoma
Interventions
First Posted Date
2016-12-05
Last Posted Date
2025-06-11
Lead Sponsor
Children's Oncology Group
Target Recruit Count
80
Registration Number
NCT02981628
Locations
πŸ‡ΊπŸ‡Έ

Children's Hospital of Alabama, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Providence Alaska Medical Center, Anchorage, Alaska, United States

πŸ‡ΊπŸ‡Έ

Banner Children's at Desert, Mesa, Arizona, United States

and more 153 locations

Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Phase 1
Completed
Conditions
Refractory Primary Central Nervous System Neoplasm
Childhood Solid Neoplasm
Refractory Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Recurrent Primary Central Nervous System Neoplasm
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2016-11-29
Last Posted Date
2025-01-14
Lead Sponsor
Children's Oncology Group
Target Recruit Count
33
Registration Number
NCT02975882
Locations
πŸ‡ΊπŸ‡Έ

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States

πŸ‡ΊπŸ‡Έ

Children's Hospital of Alabama, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Children's Hospital Los Angeles, Los Angeles, California, United States

and more 18 locations

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

Phase 2
Active, not recruiting
Conditions
Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder
Monomorphic Post-Transplant Lymphoproliferative Disorder
Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
EBV-Related Post-Transplant Lymphoproliferative Disorder
Polymorphic Post-Transplant Lymphoproliferative Disorder
Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder
Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Biological: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes
First Posted Date
2016-09-15
Last Posted Date
2024-11-07
Lead Sponsor
Children's Oncology Group
Target Recruit Count
18
Registration Number
NCT02900976
Locations
πŸ‡ΊπŸ‡Έ

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States

πŸ‡ΊπŸ‡Έ

Children's Hospital of Alabama, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Phoenix Childrens Hospital, Phoenix, Arizona, United States

and more 35 locations

Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology

Completed
Conditions
B-Cell Non-Hodgkin Lymphoma
Recurrent Childhood Acute Lymphoblastic Leukemia
Childhood Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Acute Lymphoblastic Leukemia
Childhood Acute Myeloid Leukemia
Childhood Burkitt Lymphoma
Malignant Solid Neoplasm
Interventions
Other: Informational Intervention
Other: Interview
Other: Medical Chart Review
Other: Questionnaire Administration
First Posted Date
2016-07-28
Last Posted Date
2023-07-19
Lead Sponsor
Children's Oncology Group
Target Recruit Count
530
Registration Number
NCT02847130
Locations
πŸ‡ΊπŸ‡Έ

Kaiser Permanente-Oakland, Oakland, California, United States

πŸ‡ΊπŸ‡Έ

Alfred I duPont Hospital for Children, Wilmington, Delaware, United States

πŸ‡ΊπŸ‡Έ

Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States

and more 30 locations

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Phase 1
Completed
Conditions
Refractory Malignant Solid Neoplasm
Recurrent Primary Central Nervous System Neoplasm
Childhood Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Refractory Primary Central Nervous System Neoplasm
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacokinetic (PK) study
First Posted Date
2016-06-22
Last Posted Date
2023-12-20
Lead Sponsor
Children's Oncology Group
Target Recruit Count
30
Registration Number
NCT02808650
Locations
πŸ‡ΊπŸ‡Έ

Children's Hospital of Alabama, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Phoenix Childrens Hospital, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Children's Hospital Los Angeles, Los Angeles, California, United States

and more 18 locations

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Phase 2
Active, not recruiting
Conditions
Medulloblastoma
Interventions
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Radiation: Radiation Therapy
First Posted Date
2016-03-31
Last Posted Date
2025-06-11
Lead Sponsor
Children's Oncology Group
Target Recruit Count
45
Registration Number
NCT02724579
Locations
πŸ‡ΊπŸ‡Έ

Children's Hospital of Alabama, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

USA Health Strada Patient Care Center, Mobile, Alabama, United States

πŸ‡ΊπŸ‡Έ

Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 192 locations

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

Phase 2
Completed
Conditions
Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Pharmacogenomic Study
Other: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2016-03-23
Last Posted Date
2025-04-23
Lead Sponsor
Children's Oncology Group
Target Recruit Count
196
Registration Number
NCT02717507
Locations
πŸ‡ΊπŸ‡Έ

Children's Hospital of Alabama, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Phoenix Childrens Hospital, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 88 locations

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy
Secondary Acute Myeloid Leukemia
Recurrent Childhood Acute Myeloid Leukemia
Interventions
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Other: Pharmacological Study
First Posted Date
2015-12-30
Last Posted Date
2023-09-08
Lead Sponsor
Children's Oncology Group
Target Recruit Count
38
Registration Number
NCT02642965
Locations
πŸ‡ΊπŸ‡Έ

Children's Hospital of Alabama, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Phoenix Childrens Hospital, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 70 locations
Β© Copyright 2025. All Rights Reserved by MedPath